Substrate specificity of human kallikreins 1 and 6 determined by phage display

The human tissue kallikrein (KLK) family contains 15 secreted serine proteases that are expressed in a wide range of tissues and have been implicated in different physiological functions and disease states. Of these, KLK1 has been shown to be involved in the regulation of multiple physiological processes such as blood pressure, smooth muscle contraction, and vascular cell growth. KLK6 is overexpressed in breast and ovarian cancer tissues and has been shown to cleave peptide derived from human myelin protein and Aβ amyloid peptide in vitro. Here we analyzed the substrate specificity of KLK1 and KLK6, by substrate phage display using a random octapeptide library. Consistent with earlier biochemical data, KLK1 was shown to exhibit both trypsin‐ and chymotrypsin‐like selectivities with Tyr/Arg preferred at site P1, Ser/Arg strongly preferred at P1′, and Phe/Leu at P2. KLK6 displayed trypsin‐like activity, with the P1 position occupied only by Arg and a strong preference for Ser in P1′. Docking simulations of consensus peptide provide information on the identity of the enzyme residues that are responsible for substrate binding. Bioinformatic analysis suggested several putative KLK6 protein substrates, such as ionotropic glutamate receptor (GluR) and synphilin.

[1]  Jihun Lee,et al.  Activation Profiles and Regulatory Cascades of the Human Kallikrein-related Peptidases* , 2007, Journal of Biological Chemistry.

[2]  M. Blaber,et al.  The autolytic regulation of human kallikrein-related peptidase 6. , 2007, Biochemistry.

[3]  S. Diamond Methods for mapping protease specificity. , 2007, Current opinion in chemical biology.

[4]  G. Georgiou,et al.  Substrate Specificity of the Escherichia coli Outer Membrane Protease OmpP , 2006, Journal of bacteriology.

[5]  E. Diamandis,et al.  Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.

[6]  C. Craik,et al.  Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences* , 2006, Journal of Biological Chemistry.

[7]  M. Blaber,et al.  Substrate Specificity of Human Kallikrein 6 , 2006, Journal of Biological Chemistry.

[8]  J. Whisstock,et al.  Elucidation of the Substrate Specificity of the C1s Protease of the Classical Complement Pathway* , 2005, Journal of Biological Chemistry.

[9]  M. Blaber,et al.  1.70 Å X‐ray structure of human apo kallikrein 1: Structural changes upon peptide inhibitor/substrate binding , 2005, Proteins.

[10]  T. Kishi,et al.  Enzymatic profiling of human kallikrein 14 using phage-display substrate technology , 2005, Biological chemistry.

[11]  E. Chen,et al.  Screening for protease substrate by polyvalent phage display. , 2005, Combinatorial chemistry & high throughput screening.

[12]  K. Shoemaker,et al.  Substrate Specificity of the Escherichia coli Outer Membrane Protease OmpT , 2004, Journal of bacteriology.

[13]  E. Diamandis,et al.  Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells , 2004, Tumor Biology.

[14]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[15]  Tsutomu Hashikawa,et al.  Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. , 2003, Human molecular genetics.

[16]  E. Diamandis,et al.  Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. , 2003, Biochemical and biophysical research communications.

[17]  D. Katsaros,et al.  Parallel overexpression of seven kallikrein genes in ovarian cancer. , 2003, Cancer research.

[18]  D. Katsaros,et al.  Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Deperthes Phage Display Substrate: A Blind Method for Determining Protease Specificity , 2002, Biological chemistry.

[20]  Steven M. Thompson,et al.  Crystal Structure and Biochemical Characterization of Human Kallikrein 6 Reveals That a Trypsin-like Kallikrein Is Expressed in the Central Nervous System* , 2002, The Journal of Biological Chemistry.

[21]  J. Chagas,et al.  Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. , 2002, European journal of biochemistry.

[22]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[23]  P. Nelson,et al.  New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.

[24]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[25]  S W Scherer,et al.  Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. , 1999, Genomics.

[26]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[27]  P. Isackson,et al.  Nervous System-Specific Expression of a Novel Serine Protease: Regulation in the Adult Rat Spinal Cord by Excitotoxic Injury , 1997, The Journal of Neuroscience.

[28]  James R. Miller,et al.  Zyme, a Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer’s Disease Brain* , 1997, The Journal of Biological Chemistry.

[29]  L. Juliano,et al.  Hydrolysis of somatostatin by human tissue kallikrein after the amino acid pair phe-Phe. , 1997, The Biochemical journal.

[30]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[31]  T. Tanaka,et al.  Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. , 1997, Biochimica et biophysica acta.

[32]  S. Mok,et al.  A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer , 1996, Molecular medicine.

[33]  L. Chao,et al.  Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. , 1996, The Journal of laboratory and clinical medicine.

[34]  D. Evans,et al.  Cleavage of human kininogen fragments at Met-Lys by human tissue kallikrein. , 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[35]  L. Chao,et al.  Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. , 1992, The Journal of biological chemistry.

[36]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[37]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[38]  S. Cohen,et al.  Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. , 1980, Journal of molecular biology.

[39]  E. Diamandis,et al.  The kallikrein world: an update on the human tissue kallikreins , 2006, Biological chemistry.

[40]  G. Deléage,et al.  Characterization of prostate‐specific antigen binding peptides selected by phage display technology , 2006, Journal of molecular recognition : JMR.

[41]  F. Fiedler,et al.  Substrate specificity of porcine pancreatic kallikrein. , 1979, Advances in experimental medicine and biology.